Literature DB >> 33480608

Pain Symptoms in COVID-19.

Tülay Şahin1, Aylin Ayyildiz, Kardelen Gencer-Atalay, Cem Akgün, Haci Mustafa Özdemir, Banu Kuran.   

Abstract

OBJECTIVE: The clinical manifestations of COVID-19 range from mild symptoms to severe pneumonia and severe organ damage. When evaluated specifically for pain, the data so far have shown that myalgia, headache, and chest pain can be seen in patients at varying rates; myalgia and headache, especially, are among the initial symptoms.
DESIGN: This retrospective chart review, followed by a descriptive survey design study, was carried out by examining patients afflicted with COVID-19. After discharge, patients were asked about the severity and the body region of their pain, their use of analgesics, their mood and mental health, and their overall quality of life.
RESULTS: A total of 206 patients with a mean age of 56.24 ± 16.99 yrs were included in the study. Pain during COVID-19 was found to be higher compared with the preinfectious and postinfectious states. The most frequent painful areas were reported to be the neck and back before the infection, whereas the head and limbs during the infection. The most frequently used analgesic during infection was paracetamol. There was no relationship between the patients' pain and anxiety and depression; the quality of life was found to be worse in patients with persistent pain.
CONCLUSIONS: This study showed that the head and limbs were the most common painful body regions during COVID-19. It was also found that pain can continue in the postinfection period.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 33480608     DOI: 10.1097/PHM.0000000000001699

Source DB:  PubMed          Journal:  Am J Phys Med Rehabil        ISSN: 0894-9115            Impact factor:   2.159


  8 in total

Review 1.  Decrypting the cellular and molecular intricacies associated with COVID-19-induced chronic pain.

Authors:  Mousmi Rani; Ankit Uniyal; Vinod Tiwari
Journal:  Metab Brain Dis       Date:  2022-07-18       Impact factor: 3.655

Review 2.  COVID-19 Pandemic Increases the Impact of Low Back Pain: A Systematic Review and Metanalysis.

Authors:  Giuseppe Francesco Papalia; Giorgia Petrucci; Fabrizio Russo; Luca Ambrosio; Gianluca Vadalà; Sergio Iavicoli; Rocco Papalia; Vincenzo Denaro
Journal:  Int J Environ Res Public Health       Date:  2022-04-11       Impact factor: 4.614

3.  Back Pain among COVID-19 Positive Health Care Workers in a Tertiary Care Hospital in Nepal: A Descriptive Cross-sectional Study.

Authors:  Shriraj Shrestha; Ayush Bajracharya; Saurav Dahal; Parash Bhandari; Basanta Maharjan; Suraj Bajracharya
Journal:  JNMA J Nepal Med Assoc       Date:  2021-10-15       Impact factor: 0.556

4.  A human coronavirus OC43-derived polypeptide causes neuropathic pain.

Authors:  Veronica I Shubayev; Jennifer Dolkas; Glaucilene Ferreira Catroli; Andrei V Chernov
Journal:  EMBO Rep       Date:  2022-04-24       Impact factor: 9.071

5.  Evaluating the readability, quality and reliability of online patient education materials on post-covid pain.

Authors:  Erkan Ozduran; Sibel Büyükçoban
Journal:  PeerJ       Date:  2022-07-20       Impact factor: 3.061

6.  Functioning issues in inpatients affected by COVID-19-related moderate pulmonary impairment: a real-practice observational study.

Authors:  Antimo Moretti; Antonella Belfiore; Massimiliano Bianco; Sara Liguori; Marco Paoletta; Giuseppe Toro; Francesca Gimigliano; Giovanni Iolascon
Journal:  J Int Med Res       Date:  2022-09       Impact factor: 1.573

7.  A content analysis of the reliability and quality of Youtube videos as a source of information on health-related post-COVID pain.

Authors:  Erkan Ozduran; Sibel Büyükçoban
Journal:  PeerJ       Date:  2022-09-28       Impact factor: 3.061

8.  Musculoskeletal and Neurological Pain Symptoms Among Hospitalized COVID-19 Patients.

Authors:  Debasish Jena; Jagannatha Sahoo; Apurba Barman; Anil Gupta; Vikas Patel
Journal:  Am J Phys Med Rehabil       Date:  2022-01-24       Impact factor: 2.159

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.